BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 27477167)

  • 1. Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) in the management of primary mediastinal B-cell lymphoma: a subgroup analysis of the UK NCRI R-CHOP 14 versus 21 trial.
    Gleeson M; Hawkes EA; Cunningham D; Chadwick N; Counsell N; Lawrie A; Jack A; Smith P; Mouncey P; Pocock C; Ardeshna KM; Radford J; McMillan A; Davies J; Turner D; Kruger A; Johnson PW; Gambell J; Linch D
    Br J Haematol; 2016 Nov; 175(4):668-672. PubMed ID: 27477167
    [TBL] [Abstract][Full Text] [Related]  

  • 2. R-CHOP versus dose-adjusted R-EPOCH in frontline management of primary mediastinal B-cell lymphoma: a multi-centre analysis.
    Shah NN; Szabo A; Huntington SF; Epperla N; Reddy N; Ganguly S; Vose J; Obiozor C; Faruqi F; Kovach AE; Costa LJ; Xavier AC; Okal R; Kanate AS; Ghosh N; Kharfan-Dabaja MA; Strelec L; Hamadani M; Fenske TS; Calzada O; Cohen JB; Chavez J; Svoboda J
    Br J Haematol; 2018 Feb; 180(4):534-544. PubMed ID: 29265182
    [TBL] [Abstract][Full Text] [Related]  

  • 3. R-CHOP without radiation in frontline management of primary mediastinal B-cell lymphoma.
    Messmer M; Tsai HL; Varadhan R; Swinnen LJ; Jones RJ; Ambinder RF; Shanbhag SP; Borowitz MJ; Wagner-Johnston N
    Leuk Lymphoma; 2019 May; 60(5):1261-1265. PubMed ID: 30656983
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles.
    Cunningham D; Hawkes EA; Jack A; Qian W; Smith P; Mouncey P; Pocock C; Ardeshna KM; Radford JA; McMillan A; Davies J; Turner D; Kruger A; Johnson P; Gambell J; Linch D
    Lancet; 2013 May; 381(9880):1817-26. PubMed ID: 23615461
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Primary mediastinal large B-cell lymphoma: optimal therapy and prognostic factors in 41 consecutive Asian patients.
    Tai WM; Quah D; Yap SP; Tan SH; Tang T; Tay KW; Koo YX; Tao M; Quek R; Lim ST
    Leuk Lymphoma; 2011 Apr; 52(4):604-12. PubMed ID: 21261504
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study.
    Younes A; Thieblemont C; Morschhauser F; Flinn I; Friedberg JW; Amorim S; Hivert B; Westin J; Vermeulen J; Bandyopadhyay N; de Vries R; Balasubramanian S; Hellemans P; Smit JW; Fourneau N; Oki Y
    Lancet Oncol; 2014 Aug; 15(9):1019-26. PubMed ID: 25042202
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of FDG-PET imaging as a prognostic marker of outcome in primary mediastinal B-cell lymphoma.
    Nagle SJ; Chong EA; Chekol S; Shah NN; Nasta SD; Glatstein E; Plastaras JP; Torigian DA; Schuster SJ; Svoboda J
    Cancer Med; 2015 Jan; 4(1):7-15. PubMed ID: 25205600
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial.
    Poeschel V; Held G; Ziepert M; Witzens-Harig M; Holte H; Thurner L; Borchmann P; Viardot A; Soekler M; Keller U; Schmidt C; Truemper L; Mahlberg R; Marks R; Hoeffkes HG; Metzner B; Dierlamm J; Frickhofen N; Haenel M; Neubauer A; Kneba M; Merli F; Tucci A; de Nully Brown P; Federico M; Lengfelder E; di Rocco A; Trappe R; Rosenwald A; Berdel C; Maisenhoelder M; Shpilberg O; Amam J; Christofyllakis K; Hartmann F; Murawski N; Stilgenbauer S; Nickelsen M; Wulf G; Glass B; Schmitz N; Altmann B; Loeffler M; Pfreundschuh M; ;
    Lancet; 2019 Dec; 394(10216):2271-2281. PubMed ID: 31868632
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized phase II study of concurrent and sequential combinations of rituximab plus CHOP (cyclophosphamide, doxorubicin, vincristine and prednisolone) chemotherapy in untreated indolent B-cell non-Hodgkin lymphoma: 7-year follow-up results.
    Tobinai K; Ogura M; Itoh K; Kinoshita T; Hotta T; Watanabe T; Morishima Y; Igarashi T; Terauchi T; Ohashi Y;
    Cancer Sci; 2010 Dec; 101(12):2579-85. PubMed ID: 20942866
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Addition of rituximab to CHOP-like chemotherapy in first line treatment of primary mediastinal B-cell lymphoma.
    Lisenko K; Dingeldein G; Cremer M; Kriegsmann M; Ho AD; Rieger M; Witzens-Harig M
    BMC Cancer; 2017 May; 17(1):359. PubMed ID: 28532396
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of primary mediastinal B-cell lymphoma with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone is associated with a high rate of primary refractory disease.
    Soumerai JD; Hellmann MD; Feng Y; Sohani AR; Toomey CE; Barnes JA; Takvorian RW; Neuberg D; Hochberg EP; Abramson JS
    Leuk Lymphoma; 2014 Mar; 55(3):538-43. PubMed ID: 23734654
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A single-institution retrospective analysis of outcomes for stage I-II primary mediastinal large B-cell lymphoma treated with immunochemotherapy with or without radiotherapy.
    Binkley MS; Hiniker SM; Wu S; Natkunam Y; Mittra ES; Advani RH; Hoppe RT
    Leuk Lymphoma; 2016; 57(3):604-8. PubMed ID: 26159046
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiotoxicity with rituximab, cyclophosphamide, non-pegylated liposomal doxorubicin, vincristine and prednisolone compared to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone in frontline treatment of patients with diffuse large B-cell lymphoma: A randomised phase-III study from the Austrian Cancer Drug Therapy Working Group [Arbeitsgemeinschaft Medikamentöse Tumortherapie AGMT](NHL-14).
    Fridrik MA; Jaeger U; Petzer A; Willenbacher W; Keil F; Lang A; Andel J; Burgstaller S; Krieger O; Oberaigner W; Sihorsch K; Greil R
    Eur J Cancer; 2016 May; 58():112-21. PubMed ID: 26990931
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Standard CHOP immuno-chemotherapy for primary mediastinal lymphomas].
    Schneider T; Tóth E; Lovey J; Molnár Z; Deák B; Várady E; Csomor J; Matolcsy A; Lengyel Z; Petri K; Gaudi I; Rosta A
    Orv Hetil; 2011 May; 152(19):735-42. PubMed ID: 21498163
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group.
    Pfreundschuh M; Trümper L; Osterborg A; Pettengell R; Trneny M; Imrie K; Ma D; Gill D; Walewski J; Zinzani PL; Stahel R; Kvaloy S; Shpilberg O; Jaeger U; Hansen M; Lehtinen T; López-Guillermo A; Corrado C; Scheliga A; Milpied N; Mendila M; Rashford M; Kuhnt E; Loeffler M;
    Lancet Oncol; 2006 May; 7(5):379-91. PubMed ID: 16648042
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Primary mediastinal B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: results of the Mabthera International Trial Group study.
    Rieger M; Österborg A; Pettengell R; White D; Gill D; Walewski J; Kuhnt E; Loeffler M; Pfreundschuh M; Ho AD;
    Ann Oncol; 2011 Mar; 22(3):664-670. PubMed ID: 20724576
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Favorable outcome of primary mediastinal large B-cell lymphoma in a single institution: the British Columbia experience.
    Savage KJ; Al-Rajhi N; Voss N; Paltiel C; Klasa R; Gascoyne RD; Connors JM
    Ann Oncol; 2006 Jan; 17(1):123-30. PubMed ID: 16236753
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Young patients with non-germinal center B-cell-like diffuse large B-cell lymphoma benefit from intensified chemotherapy with ACVBP plus rituximab compared with CHOP plus rituximab: analysis of data from the Groupe d'Etudes des Lymphomes de l'Adulte/lymphoma study association phase III trial LNH 03-2B.
    Molina TJ; Canioni D; Copie-Bergman C; Recher C; Brière J; Haioun C; Berger F; Fermé C; Copin MC; Casasnovas O; Thieblemont C; Petrella T; Leroy K; Salles G; Fabiani B; Morschauser F; Mounier N; Coiffier B; Jardin F; Gaulard P; Jais JP; Tilly H
    J Clin Oncol; 2014 Dec; 32(35):3996-4003. PubMed ID: 25385729
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone with or without radiotherapy in primary mediastinal large B-cell lymphoma: the emerging standard of care.
    Vassilakopoulos TP; Pangalis GA; Katsigiannis A; Papageorgiou SG; Constantinou N; Terpos E; Zorbala A; Vrakidou E; Repoussis P; Poziopoulos C; Galani Z; Dimopoulou MN; Kokoris SI; Sachanas S; Kalpadakis C; Dimitriadou EM; Siakantaris MP; Kyrtsonis MC; Dervenoulas J; Dimopoulos MA; Meletis J; Roussou P; Panayiotidis P; Beris P; Angelopoulou MK
    Oncologist; 2012; 17(2):239-49. PubMed ID: 22282906
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
    Coiffier B; Lepage E; Briere J; Herbrecht R; Tilly H; Bouabdallah R; Morel P; Van Den Neste E; Salles G; Gaulard P; Reyes F; Lederlin P; Gisselbrecht C
    N Engl J Med; 2002 Jan; 346(4):235-42. PubMed ID: 11807147
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.